The Oncology Institute Appoints Experienced Healthcare Executive Kim Tzoumakas to Board
summarizeSummary
The Oncology Institute, Inc. has appointed Kim Tzoumakas, a seasoned executive with over two decades of leadership in oncology and pharmacy services, to its Board of Directors.
check_boxKey Events
-
New Director Appointed
Kimberly Tzoumakas has been appointed to the Board of Directors of The Oncology Institute, Inc., effective February 23, 2026.
-
Extensive Healthcare Expertise
Ms. Tzoumakas brings over two decades of executive leadership experience across oncology, pharmacy services, and healthcare operations, including previous CEO roles at VytlOne National Pharmacy Services and 21st Century Oncology.
-
Independent and Qualified
The Nominating and Corporate Governance Committee determined Ms. Tzoumakas meets Nasdaq independence requirements and possesses the expertise to contribute effectively to the Board.
-
Standard Director Compensation
Ms. Tzoumakas will participate in the company's non-employee director compensation program, receiving $75,000 per annum and restricted stock unit awards to be granted at a later date.
auto_awesomeAnalysis
The appointment of Kim Tzoumakas significantly strengthens The Oncology Institute's Board of Directors. Her extensive executive leadership experience in oncology and pharmacy services, including her prior role as CEO of 21st Century Oncology, directly aligns with the company's strategic goals of expanding its care delivery model and growing its pharmacy business. This move follows a recent pattern of the company actively enhancing its board with seasoned professionals, signaling a focus on robust governance and strategic oversight.
At the time of this filing, TOI was trading at $2.52 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $250.9M. The 52-week trading range was $0.60 to $4.88. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.